Samarbetet omfattar utveckling av långtidsverkande läkemedel baserat på Camurus teknologiplattform, FluidCrystal^{®}, och Lillys läkemedelssubstanser Camurus är berättigat till upp till 870 ...

· Samarbetet omfattar utveckling av långtidsverkande läkemedel baserat på Camurus

Novel FluidCrystal technology to power next-gen incretin therapies. Partnership includes $290M upfront and milestone payments. See development pipeline details.

A new partnership between Camurus and Eli Lilly aims to develop long-acting incretin products for treating cardiometabolic health, enhancing options for patients.

Camurus expands its collaboration with Eli Lilly by including amylin receptor agonists in their partnership, enhancing cardiometabolic drug development.

Camurus has announced an expansion of its collaboration with Eli Lilly, incorporating amylin receptor agonists into their agreement. This strategic move enhances the partnership's scope.

Camurus collaborates with Eli Lilly to develop long-acting incretin therapies for metabolic health, with potential earnings reaching $870 million.

David Petrus Ibars/iStock via Getty Images Eli Lilly (NYSE:LLY) has signed a licensing and development agreement with Camurus to develop long-acting incretin products for conditions such as obesity, diabetes, and other metabolic diseases based on the latter's FluidCrystal technology. The deal allows Lilly to develop up

#logitech #webcam #c310 #720p #30fps #fluidcrystal #rightlight #shopee #deal0đ #lazada #mãgiảmgiá #hợp tác Your browser does not support HTML video. Mua giá rẻ nhất trên Shopee tại đây: Camera webcam máy tính Logitech C310 HD 720p/30fps Fluid Crystal - Auto ánh sáng RightLight 2 Nhận hàng loạt mã giảm giá, deal 0đ trên Shopee, Lazada mỗi ngày tại: Liên hệ hợp tác: phanngoc24923@gmail.com Review Camera webcam máy tính Logitech C310 HD 720p/30fps Fluid Crystal - Auto ánh sáng RightLight

The deal gives Lilly exclusive global rights to incretin products based on Camurus’ technology

Camurus (NASDAQ STO: CAMX) announced that Eli Lilly has exercised its option to add amylin receptor agonists to their existing 2025 collaboration and license agreement using Camurus' FluidCrystal® technology.The deal now covers up to four Lilly compounds and includes up to 290 million USD in development and regulatory milestones, 580 million USD in sales-based milestones, tiered mid-single digit royalties, and a 5 million USD option payment.

Camurus (NASDAQ: CAMX) reported positive topline Phase 1b results for CAM2056, a monthly FluidCrystal semaglutide depot, in 80 participants with overweight or obesity on Nov 10, 2025. CAM2056 delivered dose-dependent reductions in body weight, A1c and fasting glucose that were comparable to or exceeded weekly semaglutide to Day 85.Key data: weight -9.3% for CAM2056 10 mg vs -5.2% for weekly semaglutide (treatment diff -4.1%, p=0.008); A1c -0.44% for CAM2056 with treatment diff -0.32% (p<0.001). Safety was generally consistent with weekly semaglutide, though the highest initiation cohort had more frequent/severe events. A Phase 2b study is planned.

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty LUND, Sweden...

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty LUND, Sweden...